🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
93.47
-4.16 (-4.26%)
Nov 20, 2026, 4:00 PM EST - Market closed
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

The strategy centers on optimized IBD and HS antibodies, including co-formulated combinations designed for strong efficacy and infrequent auto-injector dosing. IBD Phase II data are expected in Q3 next year and will guide which combinations advance to Phase III.

Akash Tewari
Analyst, Jefferies

Good afternoon, everyone. I hope everyone is having a great conference. Day two of our London Healthcare Conference. It has been really great to see the attendance, and I hope everyone is having a good set of meetings. My name is Akash Tewari. I head our pharma and biotech research efforts internally within Jefferies, and we have Cameron from Spyre, and one of our top picks in biotech. Cameron, why don't I hand it off to you for some intro remarks, and we will get started?

Cameron Turtle
CEO, Spyre Therapeutics

Sure. Thanks for having me. Always an amazing conference. Broadly, our goal at Spyre is to create a set of products that raise the bar in autoimmune disease, really by taking what we think are the best mechanisms in known diseases, creating improved versions of the antibodies against those targets, and then combining them together in what we believe are elegant co-formulated products that can be delivered on a convenient basis. We started in inflammatory bowel disease. We think we have three of the best monotherapies in this space, and we are enrolling a large study now to evaluate the pairwise combinations of each of them, which we think have the potential to be much better than today's standard of care in IBD. More recently, we have expanded our efforts in HS.

This is an area like IBD, high unmet need, irreversible consequences of uncontrolled disease, and I think it is increasingly clear that TL1A and IL-17 are two of the best mechanisms in HS. We have long-acting optimized versions of both that we will be developing as monotherapies and/or combinations, again, with the idea that we can do better than the today's standard of care.

Akash Tewari
Analyst, Jefferies

Understood. We will talk about combination approaches, and you have phase II data sets coming up. This was similar to some of the times the discussion we had with Apogee. When you think about long-acting therapies and what they provide from a health economic perspective, I feel like people think, "Well, it is a known target. This is not some high science approach." But adherence has a material impact on how payers view classes, what actual adoption ends up being, and I do not feel like it is appreciated enough. I think people are growing more aware of that in some of the conditions that Apogee went for, but I do not know if they necessarily appreciate that yet in UC and Crohn's, where, again, you actually have even more severe disease progression in some instances.

Can you talk about what you are providing for patients and payers that is unique beyond just good targets?

Cameron Turtle
CEO, Spyre Therapeutics

Yeah. I think ultimately our goal as an industry is to create products that improve the lives of patients. Nothing too complicated here. In IBD, it is a disease that every point of efficacy matters a lot. This is a disease that if it is uncontrolled, you can have resections, surgeries, fibrosis, stenosis. We have seen over the course of the last few decades, as drugs come out that are even, I think, modestly improvements over the existing standard of care, they have largely moved to those products even as the first generation went biosimilar. So we originally had HUMIRA, STELARA, and then we saw head-to-head victories by ENTYVIO, TREMFYA, SKYRIZI, and those drugs have really taken the lion's share of the market with changes in efficacy on the order of 8- 12 points, around 10 points of remission, even without improvements in convenience.

I think what these combinations have the potential to do is deliver that level of improvement, maybe even more, while moving from drugs that are delivered every couple of weeks or intravenously to being able to be delivered four times a year as auto-injectors, which I think is really a major step forward. I think very likely to improve adherence, compliance, and really reduce the downstream consequences and costs of disease that, as I mentioned, are extraordinarily costly. So I think this is a better product for patients, it is a better product for payers, and ultimately, I think they should be highly valuable and used broadly.

Akash Tewari
Analyst, Jefferies

Understood. I think a part of that is your team seems to be adamant that this really is a frontline drug opportunity. I think if you tell that to someone who maybe was not familiar with your regimens, they will always be like, "Oh, come on. There are biosimilars out there. There is HUMIRA out there. Why would anyone be using a brand of therapy in a frontline setting?" Can you talk about why you are confident that really the combination approach you are delivering is actually optimally a frontline regimen? Do you feel like that is increasingly recognized when you think about external discussions?

Cameron Turtle
CEO, Spyre Therapeutics

Yeah. I think over the last, it is over a decade now that the IBD field has moved towards top-down therapy. This really comes on the back of the PROFILE study, which is the most important clinical study, but I think it reflects on a great deal of evidence before that. The PROFILE study showed that using the best drug first leads to better long-term outcomes by a meaningful margin. They did not just show that in terms of patient outcomes, clinical outcomes. They also showed that it was cost-effective too, reducing surgeries, reducing hospitalizations. Again, to make this argument to the payers, these somewhat apparently could be minor improvements in efficacy matter a lot and lead to better products and better cost-effectiveness.

I think as we look forward, even as those first-generation drugs went biosimilar and go to a meaningfully different price point, that did not slow the growth of ENTYVIO, TREMFYA, SKYRIZI. I think in the next generation here, again, I think we can come out with products that beat those by a similar or greater margin, frankly, and be launching at the same time those drugs are still branded. I think we can be launching combinations at a more similar price point, actually, as those existing branded drugs, beat them by a clinically meaningful amount on efficacy, and I think those drugs will end up taking the lion's share. I say we see data more and more in IBD, even saw it just a few weeks ago from AbbVie's combination, that the separation that we see early in these patients tends to widen over time.

Again, pointing to you want to get people on the most effective drug as soon as you can, and you want to keep them there to avoid the consequences of this disease.

Akash Tewari
Analyst, Jefferies

Understood. Last question again, in terms of where the products you have can really fit. One of the things we have noticed about J&J and their oral IL-23, which is a beautiful drug, they are running mild studies. So you are seeing appetite with oral biologic-like drugs, not just to be in the moderate to severe population, but really, and probably at even a lower cost, go for a mild, truly naive segment of patients. I think that is getting increasingly understood with oral, but I do not feel like it is talked enough about with long-acting injectables. How much has your team thought about that in terms of it being a market opportunity? Do you have maybe downstream plans to actually run studies in that population?

Given the safety profile, let's say even for the ENTYVIO or IL-23, where do you think biologic adoption could be in that population, which I don't think investors really model at all right now?

Cameron Turtle
CEO, Spyre Therapeutics

Yeah, I think in IBD, we're quite a ways away from complete penetration of advanced therapies. In ulcerative colitis, we're still below 50% in terms of the population receiving advanced therapies. In Crohn's, we're doing better. We're more like 2/3 of the population receiving advanced therapies there. But those numbers are going up as we learn more that you want to be on effective therapies early. I think oral therapies can be a helpful tool to actually get those numbers higher. That said, in IBD, there hasn't been a case where convenience alone is good enough, or you'd be willing to sacrifice safety or efficacy in exchange for convenience. I think in IBD, it is safety and efficacy first by quite a margin, and then if they're the same, we see convenience matter. So I think you and others follow the competition between the IL-23 classes.

We see drugs that are both delivered Q8W, one as an on-body pump, one as an auto-injector. The auto-injector wins by a fair margin. Similar safety and efficacy, but the auto-injector wins. So when we look at the profile of our combination therapies, having long-acting co-formulatable versions of both of these at high concentrations, we think we're uniquely able to get these into auto-injectors and deliver them subcutaneously, infrequently, and conveniently. Others who didn't start at the same place we did, with long-acting versions that we designed for co-formulations from the outset, you see a lot of combinations that are more combinations of convenience, basically combining what they had on their shelf at the same time. Things being repurposed from other indications, not designed for IBD, drugs with different dosing intervals.

I think at worst, mixing orals and injectables, that it's hard to imagine how that gets to a convenient profile. I think our setup is unique. It is a bit of we were at the right place at the right time when the combo studies came out and showed that this was going to be the future, but we were able to pick antibodies that I think give us a unique product profile relative to everything else in development.

Akash Tewari
Analyst, Jefferies

Now, it is funny. A few years ago, this idea of contribution of components, which is almost a purposely vague term in the side of the FDA, but there is something that it just seems nonsensical, at least to me, is that you go with a bispecific, you do not have to show contribution of components, you have higher ADAs, you often have higher viscosity, you can have worse dosing. Then seemingly the bar of a co-formulation is this draconian, it has to be stat sig on the contribution of components. That would be, let us say, the pitch not getting more data. We have actually gotten several datasets on how the FDA thinks about contribution of components, specifically in I&I, over the last two years. Talk to us about what your team has learned. What is really the bar on contribution of components?

Remind us in terms of your assumptions for the phase IIs going reading out next year about what you expect the combo approaches to show over the monotherapy options.

Cameron Turtle
CEO, Spyre Therapeutics

Yeah. At the high level, I do think it is unusually challenging in terms of what should be required for this relative to multi-specific antibodies, which I think have more downsides than the co-formulations do. I think we have solved it in what I think is a pretty elegant trial that does it all together, and that lets us answer this question in a very efficient way in terms of studying three monotherapies, three combos, and one placebo. I think one thing that is maybe not appreciated when we clarified our timing for reading out this study in third quarter of next year is that means we will have enrolled north of 600 patients in less than a year on this trial.

I think it speaks to the enthusiasm of this community to participate in a study testing these three combinations and their differentiation relative to what else is out there being studied. In terms of what we need to see, best-case scenario, of course, you hit stat sig contribution of components. I think super clear answer. That said, I think we have seen examples both in I&I, certainly outside of I&I, that it is a totality of evidence. I think we have clear guidance towards that as well, that it is a totality of evidence, not necessarily stat sig on any particular endpoint that you need to achieve to be able to demonstrate contribution of components. I think if we see it, easy answer. If we do not, I actually think we know what the worst-case scenario is. We have seen it with other studies in IBD.

Even if you don't hit it, there's a reasonable path forward here. We see that in the phase III study that J&J's launched, the DUET ENCORE study. Still a reasonable design, two arms, nothing extraordinarily challenging. I think we've designed the study well to achieve contribution of components. I think we're hopeful that we'll see that. If we don't, I think we still have a very viable path forward.

Akash Tewari
Analyst, Jefferies

Understood. Just remind us, in terms of the bar for phase II versus phase III, because it does seem like phase III, well-powered, is different than a phase II. What are the phase II power to show in terms of what would be a stat sig improvement on contribution components? Then what has your team thought about in terms of what you'd want to see ideally to move forward into phase III and feel confident that you could power to be stat sig?

Cameron Turtle
CEO, Spyre Therapeutics

Yeah, so we're powered to about 80% to see a mid-teens delta between these arms. This is monotherapies against placebo or the combinations against the monotherapies. We have three shots at it, right? We have three combinations, three monotherapies. I think we have many ways that this could work well. I think in terms of the bar, in terms of what would be attractive enough as a winning product, I come back to what we've seen commercially, which is that head-to-head victories in the range of 10%.

Some not even 10%. Again, in the VARSITY study, ENTYVIO beats HUMIRA by eight, and you still see that that product has massive uptake in the market and grows really rapidly, even as HUMIRA goes biosimilar. I think the ultimate bar is about a 10-point delta between the combinations and the best monotherapies. I think it's very likely that combinations can deliver that.

Akash Tewari
Analyst, Jefferies

Okay, understood. Now, talk to me a bit about what we've learned about TL1A, right? There are areas where it works, there are areas where it doesn't, TNF refractory versus naive. Where do you feel like TL1A really delivers in terms of best-in-class efficacy? Why would I take a TNF when I can take something that's theoretically safer? And where are there areas where, you know what, there's limitations on what this MOA can really deliver for patients?

Cameron Turtle
CEO, Spyre Therapeutics

Yeah, I'm trying to add them up in my head right now. I think we've seen eight different indications for-

Akash Tewari
Analyst, Jefferies

Yeah

Cameron Turtle
CEO, Spyre Therapeutics

TL1A between UC, Crohn's, and then six ex-IBD indications this year, with at least one more to come and then maybe a couple more down the road. I think if we stack rank them, I think the IBD results, one of the best, if not the best mechanism in IBD. I think HS is next. Actually, we see results where the efficacy looks in line with the best mechanisms in the space, and safety might even be cleaner there. And then below that, things that have not looked as good. I think the RA result might be next, actually, after HS. It hit the primary and some key secondaries there.

I think broadly, we wanted to explore the biology of TL1A, as everyone else did who owns it, but I think the right thing to do from a shareholder perspective is only advance the molecule either as a monotherapy or a combo when it is a best-in-indication or near best-in-indication product. I think certainly in IBD, certainly in HS. Let's see on some of these other studies that we'll read out if we have that opportunity as well.

Akash Tewari
Analyst, Jefferies

Understood. I got to give you credit because before we even got the AbbVie data and we got the UEGW abstract from that Spain dataset, I still remember even well in last year, you're like, "Look, people are underrating ENTYVIO. We love this MOA. It's combinable." You even said, I distinctly remember you saying, "If I had a choice of picking, I would take an ENTYVIO and IL-23, simply because we just don't have enough long-term data on TL1A, and these assets are more de-risked." Now, tell me, does that mean we don't know what to combine with TL1A? Or actually, when you look at some of the combination datasets we've seen, when we understand more about TL1A biology, do you feel like Spyre actually has a differentiated view on where TL1A combinations fit? Or that's still up in the air? Call your shot again.

Cameron Turtle
CEO, Spyre Therapeutics

I would say our basic hypothesis is that better components are going to make better combinations.

Doesn't have to be the case. You may see weird synergies and unexpected things with combinations, but I think it's a reasonable place to start to take the best individual components, combine them together, especially if they have orthogonal biology.

And again, a little bit lucky that the ones that we're working on do. Again, I have been biased towards α4 for a while because it's such a unique mechanism in IBD. It's a trafficking mechanism relative to these inflammatory cytokines. So I think the probability that that's going to be additive with the anti-cytokine agents, I believe, is very high. I believe it will add to both of these components. So I said I liked α4 and IL-23. I think we now have very good evidence that that's likely to work in Crohn's. I think it's just as likely, if not more so, to work in ulcerative colitis, where α4β7 might be even better. I still wouldn't say that TL1A are not going to add up as well. As an individual mechanism, TL1A might be the best of the three.

I think it is quite likely to add with the other two as well. We do not pick our favorite child yet. That is why we are testing them head-to-head against each other. I think my base case actually is we are going to have more than one of the best combinations in this space, and I think our base case is that we will be advancing more than one of these to phase III, and I think they could be some of the best products ultimately.

Akash Tewari
Analyst, Jefferies

But a finer point. Okay, so let us say IL-23 and ENTYVIO, your number one option right now, based on the evidence we have seen. What would be, because you have three combos reading out next year, if you are going to look at the scientific literature, the emerging data, where do you also feel like you could deliver best-in-class efficacy?

Cameron Turtle
CEO, Spyre Therapeutics

Yeah, you mean with these combinations? Ulcerative colitis and Crohn's, obviously, this is the right place for them. We are going to use the data next year as the primary determinant of what advances. We have all these hypotheses about the biology, but we are testing them head-to-head in a controlled trial. That is by far the best evidence. I think we will have that before anyone else, and I think the nice thing is that regardless of what wins, I think we have the optimized version of it. There is not a better version of one of these combos out there, and so we will both be first and best with whichever combo we choose to advance first.

When we advance to phase III, we are expecting to advance the first one, and then realistically, as soon as we stop enrolling the first combination in phase III, I think we can move on to the second.

and so on. I think we actually have quite a lead on many of these combinations, and I think we may have multiple of them on market before others do.

Akash Tewari
Analyst, Jefferies

How much, when we think about the combinations you ultimately move into phase III, to your point, DUET, there's a clear refractory signal that we're seeing. Now, your team's talked about, we want to be biologic-like price, frontline setting for one of these combos. But you have the opportunity to stratify the market where it's like, "Hey, we have a frontline regimen, then we also have a regimen that might work particularly in refractory patients who have been already on multiple biologics." Is that a possibility when we think about which assets you end up moving forward? Or really, it's all going to be about the frontline potential when we think about moving into phase III?

Cameron Turtle
CEO, Spyre Therapeutics

Yeah. When you look at the distribution of revenue in IBD, the top three drugs take more than 2/3 of it, and they kind of always have. It's a little bit dealer's choice in terms of which drug physicians want to start on, and then the most likely thing that they pick next is another of those top three drugs. Then when they lose response to that, the most likely thing they move to is the third-best drug in that space. I think today, we've talked about which biologics that are. I do think in 5- 10 years, those are going to be combo one, combo two-

combo three. These drugs are going to deliver greater efficacy than the existing monotherapies on the market. We have great evidence that treating early with more effective drugs leads to better long-term outcomes, and they're cost-effective. I think we can price these combinations rationally, and I think they can be multiple early-line products, and then only would you use these monotherapies after you've exhausted your potential for combinations.

Akash Tewari
Analyst, Jefferies

Okay.

Cameron Turtle
CEO, Spyre Therapeutics

I think most likely folks are going to pick whatever combination they like first, and then they'll switch to a combination with at least one new mechanism. I think we have multiple of those.

Akash Tewari
Analyst, Jefferies

Right. Now, when we think about when does Spyre get de-risked, right? It's an unusual conversation for a company that's going into phase II studies. But part of me thinks, like, look, we now have the AbbVie data. We now have emerging data about combination use. There's a growing realization about which combos work and which ones don't, right? I don't think we were in that same place when we saw the initial DUET data, and we're all trying to read J&J's body language. I think there's been more de-risking. So, when you think about external de-risking versus you have to show that your drugs work as expected, do you feel like there has already been a shift when you think about strategic discussions that we know some of these combos are going to work?

We do see the orthogonal biology, and really, we just want to make sure that the co-forms are behaving as expected, right? Has the de-risking to a certain extent already happened?

Cameron Turtle
CEO, Spyre Therapeutics

I'm not sure we've seen many data sets where combinations aren't at least somewhat additive.

Even in cases where the monotherapy components don't work very well, say in the context of you failed a great TNF, then you're getting a different TNF, and that component adds very little on its own or does very little on its own, it's still quite additive when combined with something else. We see the real-world registries in Spain. We see real-world registries all over the world where combos are at least partially additive. It also should not be surprising.

This is a heterogeneous disease with multiple pathways driving the advancement of the disease. Blocking more than one pathway should be additive. I think this AbbVie data is the strongest evidence, but the VEGA study was great evidence too. Look, I think we've had increasing evidence over time that combinations are going to be additive. I think the design of our study, we're going to have 50%-60% naive patients in our trial, 40%-50% refractory, but we'll limit the number of patients who will have failed our existing mechanisms. I think it's very likely that we're going to see a reasonable amount of additivity between the three best mechanisms in this space. I think those are going to look like good combinations.

Akash Tewari
Analyst, Jefferies

Understood. Maybe more of a question for you, because you've had a very ambitious outlook for Spyre, and I think there's good reason to think that. Part of that's been like, look, we have a moat in the sense that the capital needed to develop these co-forms, the amount of indications we're going, this is a multi-asset, multi-product story, and therefore, the strategic value, the value that you think about Spyre was always going to be larger than maybe some of your sister companies. Let's put it that way. But I think we're also seeing in terms of the error bars, right? You have a better sense of the rheum opportunity. You have the better sense of HS. You have a better sense of where the GI combos are fitting.

Do you feel like on your end too, you're also getting to a more narrow range about what you feel like Spyre can actually provide from a strategic perspective?

Cameron Turtle
CEO, Spyre Therapeutics

I do. As we talked about, eight indications for TL1A got explored over the last few years. We've seen the ones where it works best. I think the story has gotten simpler. It's basically the three best mechanisms and their combos in IBD, the two best mechanisms in HS and its combination there. I think on the IBD side, when we're launching, this is going to be about a $40 billion market, and I think the top three drugs are going to continue to take 2/3 of it or more.

HS is a much less mature market, and so the growth of that and how much combos take relative to monos is maybe a bit less certain. But in IBD, this opportunity is still massive. I still think we have three of the best, if not the best products in development there, and I think they will take a large chunk of this huge market.

Akash Tewari
Analyst, Jefferies

Understood. Just maybe lastly, okay, so there's a narrowing and let's say sharpening of what the strategic value is internally within Spyre. Is that same kind of focus in terms of sharpening what this product can deliver and an appreciation about this is really a multi-asset strategy that you could be buying, do you feel like that's getting reflected externally as well?

Cameron Turtle
CEO, Spyre Therapeutics

Look, yeah, we've had a great year in terms of appreciation for what we're doing, certainly in IBD. I think the HS story is new. But I don't think it accounts for what these could take in the ultimate market. Of course, we got to prove it out. There's always risk and time ahead to do that. But I think ultimately, these products have a potential to meaningfully move the bar forward in huge autoimmune markets. I think we can deliver huge amounts to the patients with these diseases, and then I think there's still plenty of room to grow from a valuation perspective as well.

Akash Tewari
Analyst, Jefferies

Understood. Really last question. We may be talking at the same time in London. We never know. By the time we are done with the phase IIs, do you feel like we will get to a point where both externally and internally, we are getting to the right lens about the value of this company?

Cameron Turtle
CEO, Spyre Therapeutics

No, it is always incremental, right? I think the data set that we are going to deliver next year will show how many indication-leading products we have in IBD. I think it is zero to six. There is still a reasonable amount of range there, but I think the combinations are some of the best bets in the space. I think the data we have shown in terms of proving that the monotherapies work at least as well as we expect

should de-risked that as well. More and more combination data sets showing that combos should add up. I think it is reasonably likely we are going to have multiple combinations that are leading on efficacy, leading on safety, leading on convenience, and some of the first into phase III.

Akash Tewari
Analyst, Jefferies

Understood.

Cameron Turtle
CEO, Spyre Therapeutics

I think it is a good setup.

Akash Tewari
Analyst, Jefferies

Makes sense. I agree. Hey, thank you so much. I really do appreciate it.